GlassScriptPhysician profile
Paul D Davis
NPI 1821197484
$3,527.24
in general payments reported to CMS, 2019-2025
32 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $78.84 · 2021: $369 · 2022: $798 · 2023: $489 · 2024: $823 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,025.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.66 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Amgen INC. | $343.25 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $340.55 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $264.99 | 2021-2025 | Rybelsus, Ozempic |
| Shield Therapeutics INC | $169.02 | 2024 | |
| Exact Sciences Corporation | $155.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $148.92 | 2021-2023 | Verquvo, Belsomra |
| Pfizer INC. | $111.26 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $83.38 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $61.04 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.78 | 2021 | |
| Abbott Laboratories | $57.10 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.11 | 2022-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $44.17 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $42.80 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $42.07 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.90 | 2023-2025 | Xifaxan |
| Ethicon US, LLC | $36.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2022 | |
| Amarin Pharma, INC. | $31.10 | 2020 | |
| Eisai INC. | $31.05 | 2020-2021 | |
| Mylan Specialty L.P. | $27.77 | 2019-2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $22.22 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.47 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $17.89 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.44 | 2025 | Caplyta |
| Horizon Therapeutics Plc | $16.30 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.29 | 2024 | Nuedexta |
| Novartis Pharmaceuticals Corporation | $15.24 | 2022 | |
| Organon LLC | $14.47 | 2023 | Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.41 | 2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.